| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 04/01/2004 | WO2002066480A3 2-arylamino-pyrimidines for the treatment of gsk3-related disorders |
| 04/01/2004 | US20040064039 Myocardial perfusion imaging method |
| 04/01/2004 | US20040063974 Antidepressants; anxiolytic agents; antiinflammatory agents; analgesics; antiemetics |
| 04/01/2004 | US20040063967 Antiinflammatory agents; sepsis shock; phospholipase inhibitors |
| 04/01/2004 | US20040063959 Esters and amides as PLA2 inhibitors |
| 04/01/2004 | US20040063950 Carbamates derivatived from arylakylamines |
| 04/01/2004 | US20040063949 Controlling gene expression of tranforming growth factor |
| 04/01/2004 | US20040063946 Jnk inhibitor |
| 04/01/2004 | US20040063944 Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives |
| 04/01/2004 | US20040063943 Phosphodiesterase inhibitor; cardiovascular disorders; sexual disorders |
| 04/01/2004 | US20040063941 Novel spla2 inhibitors |
| 04/01/2004 | US20040063935 Aliphatic nitrogenous five-membered ring compounds |
| 04/01/2004 | US20040063785 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (ADP-ribose) glycohydrolase, and methods for their use |
| 04/01/2004 | US20040063781 Compounds active at the glucocorticoid receptor II |
| 04/01/2004 | US20040063780 Pharmaceutical preparations for treatment of type II diabetes and methods for treatment of type II diabetes |
| 04/01/2004 | US20040063775 Five-membered heterocyclic alkanoic acid derivative |
| 04/01/2004 | US20040063773 Adminstering a pyrrole substituted 2-indolinone compound to a human for the treatment of protein kinase related cellular disorders such as cancer, autoimmune disorders, diabetes, rheumatoid arthritis, angiogenesis and osteoarthritis |
| 04/01/2004 | US20040063771 Bis-sulfonamide hydroxyethyl-amino retroviral protease inhibitors |
| 04/01/2004 | US20040063764 Halogen compounds having thrombopoietin receptor agonism |
| 04/01/2004 | US20040063759 Administering to a mammal, for treatment or prevention of conditions that can be treated or prevented by antagonizing the CCR1 receptor in a mammal, a piperidinone compound |
| 04/01/2004 | US20040063755 Aromatic compounds containing hydroxyalkylaminoalkylphenylaminophenyl group; useful for treating pre-term labor, neurological disorders and cardiac disorders |
| 04/01/2004 | US20040063752 Monotherapy for the treatment of amyotrophic lateral sclerosis with cyclooxygenase-2 (COX-2) inhibitor(s) |
| 04/01/2004 | US20040063751 Such as N-(2-cyclohexyloxynitrophenyl)methane sulfonamide |
| 04/01/2004 | US20040063748 Such as 2-(4-amino-2,3,5-trimethylphenoxy)-N-methyl-N-(4-piperidinyl)acetamide which has neuroprotective effects by inducing calcium binding proteins |
| 04/01/2004 | US20040063747 Local anesthetic methods and kits |
| 04/01/2004 | US20040063745 2-amino-4-(pyridin-2-yl)-thiazole derivatives as transforming growth factor beta (tgf-beta) inhibitors |
| 04/01/2004 | US20040063742 Such as 5-(4-Chlorophenyl)-8-methyl-6,7,8,9-tetrahydro-1-H-pyrrolo(3.2-h)isoquinoline-2,3-dione-3-oxime-(phenyl))urea; kits; drug screening |
| 04/01/2004 | US20040063741 Dopamine receptor agonist for treatment of movement disorders/Parkinson's disease |
| 04/01/2004 | US20040063736 Combination of active ingredients containing alfuzosine and apomorphine |
| 04/01/2004 | US20040063732 Such as trans-N2-(4-aminocyclohexyl)-N6-(2-aminoethyl)-1H-purine-2,6-diamine trihydrochloride for treatment/prevention of fungal diseases |
| 04/01/2004 | US20040063731 Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and endothelin receptor antagonists or thienopyrimidines and endothelin receptor antagonists |
| 04/01/2004 | US20040063727 Rheumatoid arthritis, lupus, type I diabetes, multiple sclerosis, cancer, restenosis; synthesis |
| 04/01/2004 | US20040063723 One pot synthesis; formylation, oximination, cyanation, saponification and amidation of indole ester |
| 04/01/2004 | US20040063720 Tyrosine kinase inhibitors |
| 04/01/2004 | US20040063718 Targeted therapeutics and uses thereof |
| 04/01/2004 | US20040063717 Employing fatty acid oxidation inhibitor; lowering HbA1c, glucose, total cholesterol and/or triglyceride plasma levels; increasing high density lipoprotein concentration; minimizing side effects; ranolazine |
| 04/01/2004 | US20040063716 Cholesterol biosynthesis inhibitors containing as the active ingredient tricyclic spiro compounds |
| 04/01/2004 | US20040063714 Triazolo-pyridazine derivatives as ligands for GABA receptors |
| 04/01/2004 | US20040063710 Ophthalmological preparations |
| 04/01/2004 | US20040063709 Acute and chronic inflammatory disorders; cancer |
| 04/01/2004 | US20040063707 Azaindole kinase inhibitors |
| 04/01/2004 | US20040063705 Substituted pyrimidinyl derivatives and methods of use |
| 04/01/2004 | US20040063701 Potent and specific serotonin 2 receptor inhibition with low adverse side effects; such as 1-formyl-N-(2-(4-(5H-dibenzo-(a,d)cyclohepten-5-ylidene)-1 -piperidinyl))ethylisonipecot-amide |
| 04/01/2004 | US20040063700 Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method |
| 04/01/2004 | US20040063699 Gpr14 antagonist |
| 04/01/2004 | US20040063697 Compositions of cyclooxygenase-2 selective inhibitors and thrombolytic agents for the treatment or prevention of a vaso-occlusive event |
| 04/01/2004 | US20040063696 Antiinflammatories targeting cartilage tissue; limiting side effects; arthritis, arthrosis |
| 04/01/2004 | US20040063693 5-HT2A receptor related disorders; such as 1-(2-(2-fluoro-4-nitrophenoxy)ethyl)-3-(1piperazinyl)-2(1H)-pyrazinone |
| 04/01/2004 | US20040063690 Cardiovascular disorders; guanylate cyclase activation; diseases associated with disturbed cyclic guanosine monophosphate balance |
| 04/01/2004 | US20040063687 Cardiac arrhythmias; potassium channel function inhibitors; such as 7-(3,4-Dichlorophenyl)-6-(5-fluoro-1-methyl-1H-benzimidazol-2-yl)-4,7 -dihydro-5-(methoxymethyl)pyrazolo-(1,5-a)pyrimidine |
| 04/01/2004 | US20040063679 Amidino and guanidino peptidyl compounds; autoimmune diseases |
| 04/01/2004 | US20040063671 Malonyl-coa decarboxylase inhibitors useful as metabolic modulators |
| 04/01/2004 | US20040063665 Anticancer agents; high degree of discrimination toward malignant cells; reducing side effects; nontoxic; such as 3-chloro-2-(3,4-dihydroxyphenyl)-7,8-dihydroxy-4H-chromen-4-one |
| 04/01/2004 | US20040063661 Treatment of statin side effects |
| 04/01/2004 | US20040063649 Azithromycin combination for emesis control in mammals |
| 04/01/2004 | US20040063646 Glucopyranosyloxypyrazole derivatives and use thereof in medicines |
| 04/01/2004 | US20040063644 Urea and urethane derivatives as integrin inhibitors |
| 04/01/2004 | US20040063634 Modified kertinocyte growth factor (kgf) with reduced immunogenicity |
| 04/01/2004 | US20040063633 Interleukin-18 inducing agent |
| 04/01/2004 | US20040063632 Novel tissue factor targeted thrombomodulin fusion proteins as anticoagulants |
| 04/01/2004 | US20040063623 Formulation of boronic acid compounds |
| 04/01/2004 | US20040063622 Methods and compositions for treating flaviviruses and pestiviruses |
| 04/01/2004 | US20040063621 Heterocarpine, a human ghrh-binding protein |
| 04/01/2004 | US20040063610 For therapy of mammal having a transected peripheral nerve or injured spinal cord |
| 04/01/2004 | US20040063177 Generating subtilisin mutant with decreased immunogenicity for use in laundry detergents, cosmetics and textile treatment |
| 04/01/2004 | US20040063170 Antidiabetic agents; dietetics; hypoglycemic agents |
| 04/01/2004 | US20040063135 Comprises oligonucleotides for determining concentration of glucuonidase in cell culture; detection and monitoring of malignancies and metastasis; targeted drug delivery |
| 04/01/2004 | US20040062847 Oil/fat composition |
| 04/01/2004 | US20040062824 Composition for treating chronic venous insufficiencies using an extract of red vine leaves |
| 04/01/2004 | US20040062724 Thin, flexible, multilayer film; applying, adhesion to teeth; supplying active materials |
| 04/01/2004 | US20040061039 Furnace mount and method of installation |
| 04/01/2004 | US20040060568 Hedgehog antagonists, methods and uses related thereto |
| 04/01/2004 | CA2500367A1 Agents for protection from neointimal formation in grafts comprising an nfkb dekoy |
| 04/01/2004 | CA2499213A1 Aromatic liver x-receptor modulators |
| 04/01/2004 | CA2498946A1 2,4-substituted indoles and their use as 5-ht6 modulators |
| 04/01/2004 | CA2498781A1 Indolinones substituted by heterocycles, their preparation thereof and their use as medicaments |
| 04/01/2004 | CA2498662A1 Phenol derivatives and their use as rotamase inhibitors |
| 04/01/2004 | CA2497903A1 Triazaspiro[5.5]undecane derivatives and drugs comprising the same as the active ingredient |
| 04/01/2004 | CA2496727A1 Process for producing paroxetine hydrochloride hydrate |
| 03/31/2004 | EP1403302A1 Process for producing lactic acid oligomer |
| 03/31/2004 | EP1403285A1 Fibroblast growth factor receptors |
| 03/31/2004 | EP1403279A1 Protein polymer having unfold activity on higher-order structure of protein |
| 03/31/2004 | EP1403270A1 Pde iv inhibitors |
| 03/31/2004 | EP1403269A1 Remedial agent for viral infectious disease |
| 03/31/2004 | EP1403255A1 Rho KINASE INHIBITORS |
| 03/31/2004 | EP1403252A1 Novel butadiene derivatives, process for preparation of the same and intermediates for the synthesis thereof |
| 03/31/2004 | EP1403251A1 Bis(2-aryl-5-pyridyl) derivative |
| 03/31/2004 | EP1403250A1 Bis(5-aryl-2-pyridyl) derivative |
| 03/31/2004 | EP1403249A1 Cyclic diamine compounds bearing six-membered cyclic groups |
| 03/31/2004 | EP1402913A1 Dry powder inhalation system for transpulmonary administration |
| 03/31/2004 | EP1402903A1 Method of transporting physiological polymer using protein having rxp repeated sequence |
| 03/31/2004 | EP1402902A1 Method for treatment of vascular regeneration |
| 03/31/2004 | EP1402900A1 Medicinal compositions |
| 03/31/2004 | EP1402890A1 Sulfonamide derivatives |
| 03/31/2004 | EP1402889A1 Remedies for diseases caused by nonsense mutation |
| 03/31/2004 | EP1402888A1 The use of substituted carbocyclic compounds as rotamases inhibitors |
| 03/31/2004 | EP1402887A1 New compounds for the inhibition of undesired cell proliferation and use thereof |
| 03/31/2004 | EP1402884A1 Liposome-containing remedy for the treatment of vascular diseases |
| 03/31/2004 | EP1402788A1 Body temperature-raising agent of amino acids for eating or drinking and for medical use |
| 03/31/2004 | EP1402449A2 Method, system, apparatus and device for discovering and preparing chemical compounds |